Ionis Pharmaceuticals | search
Click here to view Ionis Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Ionis shares positive clinical update from ongoing trial of ION582 for ...MIAMI , Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome.
- Corporate Presentation - Ionis Pharmaceuticals, Inc.described in additional detail in Ionis' annual report on our Form 10-K for the year ended December 31, 2023, and our most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available at www.ionis.com.
- Ionis Pharmaceuticals, Inc. FORM 10-K SECURITIES AND EXCHANGE ...Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) D e l aw are 33-0336973 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 2855 G az e l l e C ou r t, C ar l s b ad , C A 92010
- Ionis enters agreement with Roche for two novel RNA-targeted programs ...CARLSBAD, Calif., Sept. 27, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD). Roche gains exclusive worldwide ...
- Ionis announces eplontersen receives orphan drug designation from U.S ...Eplontersen (formerly IONIS-TTR-L Rx) is an investigational antisense medicine that uses Ionis' LIgand-Conjugated Antisense (LICA) technology and is designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive, and fatal disease. Ionis and AstraZeneca are currently ...
More
